Extract
The natural history of venous thromboembolism (VTE), its impact on outcome and the rationale for prophylaxis are well established for hospitalised, acutely ill medical patients [1–10], but are less clear for nonhospitalised immobilised patients. Current guidelines for antithrombotic therapy recommend the use of prophylaxis in hospitalised, acutely ill medical patients, and suggest against its use in chronically immobilised persons at home and in patients with isolated lower-leg injuries requiring leg immobilisation [11]. However, there are no suggestions on the use of VTE prophylaxis in acutely ill medical patients immobilised at home.
Abstract
Fatal PE after immobility at home was more frequent than after immobility in hospital http://ow.ly/J0UIr
Acknowledgements
The coordinator of the RIETE Registry was Manuel Monreal (Spain). The RIETE Steering Committee members were Hervè Decousus (France), Paolo Prandoni (Italy) and Benjamin Brenner (Israel). The RIETE National Coordinators were Raquel Barba (Spain), Pierpaolo Di Micco (Italy), Laurent Bertoletti (France), Sebastian Schellong (Germany), Inna Tzoran (Israel), Abilio Reis (Portugal), Marijan Bosevski (Republic of Macedonia), Henri Bounameaux (Switzerland), Radovan Malý (Czech Republic) and Philip Wells (Canada). The RIETE Registry Coordinating Center was S&H Medical Science Service, Madrid, Spain.
The members of the RIETE group were as follows. Spain: M. Alcalde-Manero, V. Andújar, J.I. Arcelus, R. Barba, M. Barrón, B. Barrón-Andrés, J. Bascuñana, A. Blanco-Molina, I. Casado, F. Conget, C. de Ancos, F. del Molino, J. del Toro, J.A. Díaz, C. Falgá, A.I. Farfán, C. Fernández-Capitán, C. Font, L. Font, P. Gallego, F. García-Bragado, V. Gómez, J. González, D. González-Marcano, E. Grau, R. Guijarro, J. Gutiérrez, L. Hernández, S. Hernández-Huerta, L. Jara-Palomares, M.J. Jaras, D. Jiménez, J.L. Lobo, L. López-Jiménez, L. López-Montes, R. López-Reyes, J.B. López-Sáez, M.A. Lorente, A. Lorenzo, M. Macià, O. Madridano, P.J. Marchena, J.M. Martín-Antorán, F. Martín-Martos, M. Mellado, M. Monreal, M.V. Morales, D. Nauffal, J.A. Nieto, M.J. Núñez, R. Otero, B. Pagán, J.M. Pedrajas, G. Pérez-Rus, M.L. Peris, I. Pons, J.A. Porras, A. Riera-Mestre, A. Rivas, M.A. Rodríguez-Dávila, P. Román, V. Rosa, N. Ruiz-Giménez, J. Ruiz, A. Sampériz, R. Sánchez, O. Sanz, S. Soler, J.M. Suriñach, G. Tiberio, R. Tirado, J. Trujillo-Santos, F. Uresandi, B. Valero, R. Valle, J. Vela, C. Vilar, A. Villalobos and J. Villalta. Argentina: P. Malfante P. Belgium: P. Verhamme and T. Vanassche. Brazil: T. Gadelha. Canada: P. Wells. Czech Republic: R. Malý and J. Hirmerova. France: L. Bertoletti, A. Bura-Riviere, F. Moustafa, D. Farge-Bancel, A. Hij, I. Mahe, A. Merah and I. Quere. Germany: S. Schellong. Israel: A. Braester, B. Brenner, I. Tzoran and D. Zeltser. Italy: A. Apollonio, G. Barillari, M. Ciammaichella, F. Dalla Valle, P. Di Micco, P. Ferrazzi, A. Guida, R. Maida, F. Pace, S. Pasca, C. Piovella, P. Prandoni, R. Re, L. Rota, E. Tiraferri, D. Tonello, A. Tufano, A. Visonà and B. Zalunardo. Portugal: A. Mondragão, J.L. Ribeiro de Almeida and M.S. Sousa. Republic of Macedonia: M. Bosevski and M. Zdraveska. Switzerland: A. Alatri, H. Bounameaux, L. Calanca and L. Mazzolai. Venezuela: J.C. Serrano.
We thank S&H Medical Science Service for their quality control data, logistic and administrative support.
Footnotes
Support statement: We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG's support was limited to the part of RIETE outside Spain, which accounts for a 21.94% of the total patients included in the RIETE Registry. Funding information for this article has been deposited with FundRef.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received November 28, 2014.
- Accepted January 29, 2015.
- Copyright ©ERS 2015